7 results
8-K
EX-1.1
PNT
POINT Biopharma Global Inc.
14 Sep 22
POINT Biopharma Prices Public Offering of Common Stock
4:14pm
as to the matters covered thereby.
(lii) Cybersecurity. Except as would not, in the aggregate, reasonably be expected to have a Material Adverse
S-3
EX-1.2
PNT
POINT Biopharma Global Inc.
1 Jul 22
Shelf registration
4:13pm
as to the matters covered thereby.
(liii) Cybersecurity. Except as would not, in the aggregate, reasonably be expected to have a Material Adverse Effect
DEF 14A
PNT
POINT Biopharma Global Inc.
28 Apr 22
Definitive proxy
8:36am
initiatives and significant cybersecurity risks and any disclosure obligations arising from such risks;
reviewing the Company’s compliance and ethics
8-K
EX-1.1
PNT
POINT Biopharma Global Inc.
10 Jul 20
Therapeutics Acquisition Corp., Sponsored by RA Capital Management, L.P., Announces Pricing of Upsized $118 Million Initial Public Offering
5:17pm
or commission as a result of any transactions contemplated by this Agreement.
(vv) Cybersecurity. The Company’s information technology assets and equipment
S-1
EX-1.1
3ucpzla9 yyj6r
15 Jun 20
IPO registration
5:28pm
- Prev
- 1
- Next